Introduction {#s1}
============

Multiple Sclerosis (MS) is a chronic autoimmune mediated disease of the Central Nervous System (CNS) characterized by inflammation, demyelination, and axonal loss (McFarland and Martin, [@B87]). Although its etiology remains unknown, several lines of evidence support the notion that autoimmunity plays a major role in disease development and susceptibility. It is generally accepted that both MS and experimental autoimmune encephalomyelitis (EAE), an animal model resembling MS, involve Th1 and Th17 cells recognizing certain myelin sheath components (Goverman, [@B53]). Autoimmune diseases such as MS are currently thought to be caused by a combination of individual genetic susceptibility and external environmental factors (Marrie, [@B82]; Oksenberg and Baranzini, [@B94]). The genetic component of MS is believed to result from the action of common allelic variants in several genes. However, discordance of MS among monozygotic twins suggests that additional factors, such as environmental modulators could be involved (Oksenberg and Baranzini, [@B94]).

Several studies implicate infectious and non-infectious environmental factors present during childhood and young adulthood as strong determinants of MS risk, although their exact nature remains unidentified. Microbial infections can act as triggers inducing or promoting autoimmunity, resulting in clinical disease manifestations in genetically predisposed individuals. Alternatively, infections could accelerate sub-clinical autoimmune processes (Christen and von Herrath, [@B24]; Correale et al., [@B30]). In contrast to this view, epidemiological and experimental evidence has accumulated in recent decades indicating a steady increase in autoimmune disease incidence in developed countries, which have been associated to a decline in infectious disease prevalence (Bach, [@B8]). These observations suggest infections may protect rather than induce or accelerate autoimmune diseases like MS.

Several studies both in humans and in animal models have shown helminths to be powerful modulators of host immune responses (La Flamme et al., [@B72]; Sewell et al., [@B106]; Jankovic et al., [@B64]). Following this premise, we recently demonstrated that helminth-infected MS patients showed significantly lower disease activity, compared to uninfected MS subjects (Correale and Farez, [@B26]). In addition, we provided evidence that autoimmune response down-regulation, secondary to parasite infection in MS patients was mediated through regulatory cell activity, the effect of which extended well beyond classical response to pathogens (Correale and Farez, [@B26]).

Dendritic cells (DCs) in parasite infected hosts express a range of pattern recognition receptors (PPRs), including Toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), retinoic acid-inducible gene-like receptors (RIG-like receptors), and C-type lectin receptors (CLRs). Upon engagement, signaling cascades are triggered inducing gene expression involved in DC maturation, and in priming and skewing regulatory T cell immune responses (Kane et al., [@B66]). The fact that helminths can both activate and negatively regulate TLR expression indicates just how a tight control over the immune response these infections exert.

Basic immunology of MS
======================

Plaques of inflammatory demyelinitation within the CNS are the pathologic hallmarks of MS. Typical features of the acute plaque include ill-defined margins of myelin loss, infiltration by immune cells, and parenchymal edema (Frohman et al., [@B45]). The constituents of immune cell influx around vessels include T cells, B cells, monocytes, and macrophages. The presence of lymphocytes within plaques and bordering areas suggests inflammatory destruction observed in MS is driven by antigen-specific cells targeting myelin and other CNS components. The determination that EAE can be mediated by CD4+ T cells has promoted intense investigation into potential CD4 T-cell targets in MS. However, how these T cells become abnormally activated against CNS antigens remains unclear. New research has focused on the different roles of CD4+ T cell subsets in MS. Following activation, naïve T cells differentiate into various T cell populations with different effector functions (Boppana et al., [@B17]). Th1 cells produce pro-inflammatory cytokines such as IFN-γ activating macrophages. Th2 cells secrete anti-inflammatory cytokines such as IL-4. Dysregulation of the balance between Th1 and Th2 cytokines has long been implicated in MS immunopathogenesis. Th17 represents a distinct lineage of effector T cells. IL-23 produced by macrophages and DCs is critical for expansion of Th17 cells synthesizing pro-inflammatory cytokines such as IL-17A and IL-17F (Korn et al., [@B70]). Interestingly, Th17 to Th1 ratio appears to be a critical determinant of CNS inflammation, with high Th17 to Th1 ratios linked to T cell infiltration and CNS inflammation (Strommes et al., [@B109]). Cytotoxic CD8+ T cells which are present in MS lesions in significant numbers may also contribute to tissue damage by attacking oligodendrocytes and transecting axons (Babbe et al., [@B6]; Neumann et al., [@B92]).

Natural occurring regulatory T cells (CD4+CD25+ FoxP3+; Treg) comprise a small number of CD4+ T cells that have been implicated in MS pathogenesis. Although Treg cell numbers in peripheral blood and CSF appear to be similar in MS patients and in healthy controls, several studies point to defects in the capacity of Tregs from MS patients to suppress myelin-specific T cell activation in the periphery (Viglietta et al., [@B114]). In addition to CD4+CD25+FoxP3+ Treg, *in vitro* antigen activation leads to Foxp3 expression in CD8+ T cells. This enables CD8+ T cells to also acquire suppressive activity (Correale and Villa, [@B31]).

Although an autoreactive T cell-mediated immune response has been considered critical for MS pathogenesis, increasing evidence indicates that B cells also play a key role, as indicated by the presence of B cells, plasma cells, immunoglobulins, and complement deposition in autopsy tissues from MS patients, along with immunoglobulin-myelin complex within macrophages (Genain et al., [@B49]). Intrathecal IgG synthesis, and the recent finding of B-cell lymphoid follicles in the meninges of MS patients with progressive disease, further support this concept (Magliozzi et al., [@B79]; Franchiotta et al., [@B43]). In addition, B cells may promote neuroinflammation in MS via secretion of pro-inflammatory cytokines such as TNF-α, and lymphotoxins in the presence of T cell-derived cytokine IFN-γ (Bar-Or et al., [@B10]). Conversely, B cells are also likely to have immune-suppressive properties. For example, IL-10 secretion by B cells can serve to limit pro-inflammatory autoreactive CD4+ T cell response (Fillatreau et al., [@B41]).

Immune access to the CNS is generally considered to be restricted. Only by engaging in a critically timed sequence of events can autoreactive lymphocytes enter the CNS compartment. Initially, leukocyte engages in rolling, activation, and arrest along the Blood-Brain Barrier endothelium. This initial step is greatly facilitated by upregulation of endothelial cell adhesion molecules, including ICAM-1 and VCAM-1 (Piccio et al., [@B98]). Changes in the vascular endothelium could result from pro-inflammatory mediators circulating within the vasculature, including TNF-α, and IFN-γ. The complex sets of molecules that leukocytes depend on for entry into the CNS are integrins, a group of molecules mediating adhesion between cells. Among a panel of leukocyte adhesion receptors, VLA-4 was identified as the crucial factor for encephalitogenic T-cell binding to the endothelium (Yednock et al., [@B121]). In addition, leukocyte migration to the CNS is increased through the action of chemokines and their receptors, which have been implicated in leukocyte influx into the CNS observed in MS (Holman et al., [@B62]).

Antigen presenting cells (APCs) also play an important role in the initiation and progression of MS. DCs are a group of APCs which modulate adaptive immune responses, usually present in perivascular spaces, the choroid plexus, and the meninges of healthy brains (Serafini et al., [@B105]). In MS, DCs among other cell types are recruited to the CNS, representing the major APCs during the secondary phase of cognate interactions with CD4+ T cells within the CNS (Greter et al., [@B55]). In addition to DCs, microglia, as resident APCs localized in active plaques, play an important role in antigen presentation. Upon activation, microglial cells express greater amounts of Class II MHC and co-stimulatory molecules, promoting pro-inflammatory T cell responses within the CNS (Lassmann et al., [@B74]).

Although MS was classically described as a disease marked by the loss of myelin, axonal loss has also been observed even in the earliest pathology reports on the disease (Charcot, [@B21]). Mechanisms for axonal damage are manifold and include: a specific immunological attack on axons (Medana et al., [@B88]; Neumann et al., [@B92]); the presence of soluble mediators such as proteases and free radicals released as part of the inflammatory environment present in the CNS of MS patients (Smith and Lassmann, [@B107]), or lack of neurotrophic factors provided to the axon by oligodendrocytes as a result of demyelination (Frohman et al., [@B44]). As a consequence of immune-mediated injury to myelin, higher energy demands on demyelinated axons and glutamate-mediated excitotoxicity may impart further unsustainable damage (Werner et al., [@B119]; Mahad et al., [@B80]).

Figure [1](#F1){ref-type="fig"} summarizes the most important mechanisms involved in MS pathogenesis.

![**Mechanisms involved in MS pathogenesis. (1)** Peripheral activation; **(2)** Migration of activated lymphocytes across the Blood-Brain-Barrier; **(3)** Reactivation of lymphocytes in the CNS and secretion of pro-inflammatory mediators; **(4)** Induction of demyelination; **(5)** Induction of axonal damage.](fcimb-02-00112-g0001){#F1}

The EAE model
=============

Dissecting the pathogenesis of a disease as complex as MS in humans is fraught with many problems, particularly those associated with clinical and genetic heterogeneity. Because brain and spinal cord tissue cannot easily be sampled in MS patients *in vivo*, a number of animal models have been generated to provide insights into the underlying pathology, as well as to identify surrogate biomarkers and therapeutic targets. The basic protocol for inducing EAE involves immunizing animal strains/species using either foreign or self proteins from the white matter of the nervous system, usually myelin basic protein (MBP), proteolipid protein (PLP), or myelin oligodendroglial glycoprotein (MOG; Steinman, [@B108]). Immunization leads to the development of a disease state in the animals which shows physical and neuropathological similarities to human MS. Clinical course varies from acute monophasic episodes of paralysis in some, to chronic-relapsing neurological episodes and progressive disability in others (Furlan et al., [@B46]). The episodes correlate with the perivascular mononuclear cell infiltrates in the CNS and in some species and strains extensive myelin destruction and axonal loss (Mix et al., [@B90]). After an initial period of experimentation with active sensitization, murine models of chronic demyelination progressed to adoptive-transfer technologies, whereby CNS antigen-specific bulk-isolated lymphocytes, T cell lines or T cell clones were administered intravenously into naïve recipients (Brown and McFarlin, [@B18]). Recently, transgenic murine models have been developed in which disease arises spontaneously, mostly through insertion of myelin-specific human T cell receptors and human histocompatibility complex antigens (Ellmerich et al., [@B38]; Pöllinger et al., [@B99]).

Although many features of EAE reflect what is known about the pathophysiology of MS, discrepancies between EAE and MS remain. Extrapolations must therefore be made with caution when predicting what might happen in MS, based on results obtained in EAE (Baker et al., [@B9]). One critical limitation is that most EAE studies use injection with antigenic material to induce disease onset. This clearly contrasts with the spontaneously arising nature of MS. Transgenic murine models offer a possibility to overcome this limitation. However, these are highly manipulated mice and the exact antigen(s) involved in MS is not yet known, generating limitations in the use of models. Another potential limitation is that EAE research is mostly conducted on highly inbred animals (Handel et al., [@B57]). Finally, the degree of clinical disease in the EAE model is typically reflected by the lesion load within the spinal cord (Allen et al., [@B5]). Although some animal strain/species may particularly develop cerebellar lesions, the brain in many EAE models is relatively unaffected (Betelli, [@B13]). Problematic aspects of animal models are in no way confined to MS alone, and limitations in models should be acknowledged when placing research findings into perspective. Clearly, studies on EAE, despite relative ease, are no substitute for research on bona fide specimens from MS patients.

Helminth infections modulate immune response and alter clinical course of MS
============================================================================

The best evidence on parasite infections causing immune response modulation in autoimmune diseases derives from animal models. Pre-established infection with the helminth *Schistosoma mansoni*, or pre-treatment of mice with *S. mansoni* ova significantly attenuates clinical course, reduces incidence and delays onset of EAE in mice, and is associated with decreased IFN-γ, TNF-α, IL-12 and nitric oxide production by splenocytes, as well as increased production of IL-10 and TGF-β (La Flamme et al., [@B72]; Sewell et al., [@B106]). Moreover, IL-12p40 transcript levels are dramatically reduced in the spinal cord of *S. mansoni* infected animals, correlating with decreased macrophage-infiltrates in brain and spinal cord. Although CD4+ T cell levels are similar during the disease peak, they fall significantly 6 week post-stimulation, suggesting schistosomiasis may affect EAE course by targeting the macrophage compartment, and down-regulating effector functions mediated by T cells. Likewise, infection with *Fasciola hepatica* also exerts bystander suppression of immune responses to autoantigens and attenuates clinical signs of EAE (Walsh et al., [@B115]). Protection is associated with autoantigen IFN-γ and IL-17 production suppression. Th1 and Th17 response is maintained in IL10^−/−^ mice, but abrogated by *in vivo* TGF-β neutralization, indicating that *F. hepatica* induced TGF-β plays a critical role in the suppression of auto-antigen specific Th1 and Th17 responses. Similarly, in mice infected with *Taenia crassiceps* symptom severity was significantly reduced in 50% of the animals, an effect associated with decreased MOG-specific splenocyte proliferation and IL-17 as well as TNF-α production. Moreover, parasite infection induces an increased production of IL-4 and IL-10, as well as limited leukocyte infiltration in the spinal cord and brain (Reyes et al., [@B102]). Therefore, the molecular mechanisms responsible for these beneficial effects on disease course seem to differ depending on the helminth species, or helminth-derived products used, and in addition may be host and disease dependent as well.

Recent epidemiological studies demonstrated a dichotomous relationship between worldwide distribution of MS and the parasite *Trichuris trichiura*, a common human pathogen. MS prevalence appears to fall steeply once a critical threshold of *T. Trichiura* (about 10%) is exceeded (Fleming and Cook, [@B42]). Longitudinal studies including those tracking the prevalence of MS in response to changing sanitation and levels of infection would be very informative to understand the role of helminths in the modulation of MS. In this regard, the increase in MS prevalence in the French West Indies between 1978 and 1994 was correlated with a significant reduction in intestinal parasitism during the same period (Cabre et al., [@B19]). Although intriguing and provocative the data only demonstrate association, but in no way prove causality. Sanitation may simply be a marker for more fundamental social or environmental factors in developed countries that are directly linked to MS etiology (Fleming and Cook, [@B42]).

Recently, we identified a group of 12 MS patients (8 women, 4 men; mean age 34 ± 6.8 years) presenting eosinophilia subsequently determined to be caused by mild, asymptomatic intestinal parasitosis, a diagnosis confirmed in all patients by positive stool examination (Correale and Farez, [@B26]). Three patients were infected with *Hymenolepis nana*, three with *Trichuris trichiura*, three with *Ascacris lumbricoides*, two with *Strongyloides stercolaris*, and one with *Enterobius vermicularis*. At time of eosinophil count, helminth egg load values ranged between 1180 and 9340 eggs/gr of stool. Presence of other endemic parasitoses, including trypanosomiasis, leishmaniasis, amebiasis, giardasis, and toxoplasmosis, were ruled out in this population both by microscopic stool examination and serological testing. Investigations were always negative, excluding simultaneous presence of these infections. Patients were matched and compared to 12 uninfected MS subjects. Following standard medical practice as well as tropical medicine expert recommendations indicating asymptomatic adult patients usually do not require treatment, parasite infected MS patients were not given anti-helminth medication. Both groups were followed for approximately 4.5 years during which time clinical, radiological, and immunological parameters were compared. Parasite-infected MS patients showed significantly lower exacerbation rate, minimal changes in disability, and significantly lower radiological activity compared to uninfected MS individuals.

Parasite-driven protection was associated with induction of regulatory T cells, secreting suppressive cytokines such as IL-10 and TGF-β, as well as CD4+CD25+FoxP3+ T cells displaying significant suppressive function.

These findings provide evidence to support autoimmune down-regulation secondary to parasite infections in MS patients through regulatory T cell action, with effects extending beyond response to the infectious agent. Evidence of regulatory T cell presence during parasite infections is now emerging, offering a potential explanation for mechanisms through which infected hosts exhibit altered immune responses to bystander antigens.

In addition to the development of regulatory T cells, helminths also induce regulatory B cells capable of dampening the immune response through production of IL-10 in MS patients (Correale et al., [@B29]). The cytokine is essential for regulatory function development in this subset of B cells, and B cells isolated from IL-10 knock-out mice fail to show the protective function (Fillatreau et al., [@B41]). In agreement with our findings, recent observations indicate that B cells from MS patients exhibit relative deficiency in their IL-10 producing capacity (Duddy et al., [@B35]). Interestingly, production of IL-10 by B cells is restricted to helminth-infected individuals exclusively. B cells from patients with infections from other parasites such as *Trypanosoma cruzi* exhibit IL-10 levels similar to those in uninfected MS patients, indicating that intracellular parasites are unable to down-modulate harmful autoimmune responses in the way helminths do. Likewise, B cells from *paracoccidioides brasiliensis*-infected patients, although expressing Th2 immune responses after antigen-stimulation of peripheral blood mononuclear cells (PBMC), exhibited B-cell IL-10 production levels similar to those observed in uninfected MS patients, suggesting that increased production of IL-10 by B cells found in helminth-infected MS patients is not determined by the Th2 profile present in these individuals. IL-10 producing B cells isolated from helminth-infected MS patients express MHC Class Ib molecule CD1d, which is involved in antigen presentation and in immunoregulation. Glycolipids presented by CD1d expressing the invariant Vα14 (in mice), or Vα24 (in humans) T cell receptor, activate natural killer T cells, a mechanism found to prevent autoimmune responses in different animal models (Godfrey and Kroneneberg, [@B50]). Moreover, the cytoplasmic tail of CD1d is linked to signaling cascades associated to IL-10 transcription, suggesting yet another immune regulatory mechanism (Colgan et al., [@B25]).

Although these results provide clear evidence that persistent helminth infections can induce an anti-inflammatory regulatory network, consequently altering the course of MS, intervention studies are necessary to establish whether a direct link between parasites and the autoimmune response observed in MS exists. Our initial observation on helminth-infected MS patients was extended, and subjects prospectively studied for approximately 7.5 years. After 5.25 years, four patients required anti-helminth treatment. Following drug administration, clinical and radiological activity increased to levels observed in uninfected MS patients (Correale and Farez, [@B28]). Mechanistic studies revealed that cytokine secretion pattern reverted, with increase in IFN-γ and IL-12 secreting cell numbers, and a robust decline in IL-10 and TGF-β secreting cells as well as in CD4+CD25+Foxp3+ T regulatory cells. These observations provide clear evidence that chronic helminth infections induce anti-inflammatory networks, dampening inflammatory reactions occurring in autoimmune diseases. Based on the observation that increased production of IL-10 by CD4+ T cells and B cells after helminth infection induced modulation of EAE and MS, it seems reasonable to postulate recombinant IL-10 use (rIL-10) for MS patient treatment. Increased IL-10 expression in CNS during recovery from EAE-induced brain inflammation, suggests IL-10 presence is, however, required within the target organ for disease remission to occur (Kennedy et al., [@B69]). Because of their short half-life, cytokines need to be administered frequently and in large doses to provide therapeutic concentrations at the target organ level, and systemic administration of rIL-10 for treatment of EAE has yielded contradictory results. Intravenous injection of rIL-10 has exacerbated, rather than suppressed EAE (Cannella et al., [@B20]). In contrast, other studies have shown that peripheral IL-10 treatment can prevent EAE, when administered systemically during the priming phase of the disease (Rott et al., [@B104]). Should rIL-10 be of therapeutic benefit, then it would need to be administered once the autoagressive response has been generated. IL-10 also, significantly inhibited the effector phase of EAE when administered locally in the CNS using a retrovirus vector (Croxford et al., [@B32]), providing an optional manner to maintain effective levels of IL-10 when frequent injection is not feasible. These results suggest that although rIL-10 has the potential to prevent CNS inflammation, distribution, and timing of its production may explain its variable effectiveness (O\'Garra et al., [@B93]). Overall it is possible to conclude that systemic administration of rIL-10 may yield suboptimal efficacy, while targeted and persistent delivery of this cytokine in the CNS may be highly effective.

Expression of TLR in MS patients
================================

TLRs are type I transmembrane glycoproteins composed of extracellular and intracellular signaling domains (Gay and Gangloff, [@B47]). They are expressed in different combinations on many cells of the immune system, at the cell surface and along endosomal membranes. Extracellular TLR domains have reiterated leucine-rich modules bearing pathogen-associated molecular patterns (PAMPs) able to recognize a wide range of microbial products, thus providing a link between innate and adaptive immunity (Akira, [@B3]; Kawai and Akira, [@B68]). The microbial products constituting PAMPs that bind to TLR can be lipids, lipopeptides, proteins, or nucleic acids. Initially, these exogenous PAMPs were described in the context of infection, but endogenous ligands such as self-molecules from apoptotic cells can also trigger inflammation. In particular endogenous heat-shock proteins, extra-cellular matrix fragments, fibrinogen, and self RNA and DNA can bind to TLRs (Yu et al., [@B122]). Endogenous RNA and DNA are able to activate TLR7 and TLR9 if they enter endosomal compartment, inducing production of pro-inflammatory cytokines by plasmocytoid DCs (Chi and Flavell, [@B23]). In mammals, specific combinations of TLRs are expressed on immune cells such as DCs, macrophages, mast cells, and to a lesser degree in fibroblasts, epithelial cells, endothelial cells, and also in T and B cells.

The innate immune system plays an important role both in the initiation and progression of MS influencing the effector function of T and B cells (McFarland and Martin, [@B87]; Boppana et al., [@B17]). In particular, recent studies have shown that TLRs modulate MS as well as EAE (Monney et al., [@B91]; Weiner, [@B117]; Racke and Drew, [@B101]), and several endogenous TLR ligands have been recently identified in the MS lesions (Lassmann, [@B74a]). The need for the use of Complete Freund\'s adjuvant (CFA) containing mycobacteria to induce EAE suggests TLR signaling may be important for the induction of encephalitogenic Th17 cell responses and EAE. TLR4 recognizes LPS subsequently inducing a pro-inflammatory Th1 response (Marta et al., [@B84]). Unexpectedly, lack of TLR4 exacerbates Myelin Oligodendrocyte Glycoprotein (MOG)-induced EAE (Marta et al., [@B83]). TLR4^−/−^ mice exhibited marked increase in IL-6 and IL-23 expression by splenic myeloid DCs, increased frequency of splenic Th17 cells, and increased levels of serum IL-17. In contrast, MOG-specific Th1 responses are impaired in TLR4^−/−^ mice. This could explain the aggravated Th17 cell response in TLR4^−/−^, because Th1 cells and IFN-γ inhibit Th17 cell differentiation *in vitro* (Harrington et al., [@B60]).

Mycobacteria are rich in unmethylated CpG DNA that binds to TLR9. The role of TLR9 in EAE has therefore been investigated. Initial experiments demonstrated that TLR9^−/−^ mice exhibited ameliorated symptoms of MOG~35--55~ induced EAE (Prinz et al., [@B100]). In contrast, other authors demonstrated that TLR9^−/−^ mice exhibited exacerbated symptoms of MOG-induced EAE (Marta et al., [@B84]). Pro-inflammatory cytokine expression by splenic myeloid DC and T cells is similar in TLR9^−/−^ and wild-type mice, suggesting cells other than myeloid DCs or T cells are responsible for these findings (Marta et al., [@B84]). Several putative explanations for exist for these conflicting results: first, a net anti-inflammatory effect of TLR9 signaling, despite its role in pathogenic antibody production. Second, induction of cross-tolerance upon repeated stimulation of one TLR family. Finally, induction of tolerance mediated by TLR9 (Marta et al., [@B84]).

TLR regulation may be altered by helminth parasites, affecting its function and levels of expression. Our group has provided evidence suggesting that surface expression of TLR2 on both B cells and DCs is significantly higher in helminth-infected MS patients (Figure [2](#F2){ref-type="fig"}) and that exposure of either cell population to soluble egg antigen (SEA) obtained from *S. mansoni* resulted in significant upregulation of TLR2 in helminth-infected MS patients, but not in uninfected individuals (Figure [3](#F3){ref-type="fig"}; Correale and Farez, [@B27]). It is well known that a variety of pathogens can cause increased TLR expression. Some authors have found results similar to our observations, indicating higher expression of TLR2 on PBMCs, and enhanced response to the Pam3Cys ligand in *Plasmodium falciparum*-infected children, compared to uninfected counterparts (Hartgers et al., [@B61]). Other reports, however, show down-regulation of TLR expression to be an important immune evasion strategy induced by some protozoan parasites, and also by filarial parasites (Babu et al., [@B7]). Interestingly, cells from uninfected subjects did not exhibit alterations in TLR expression. It is feasible that TLRs become desensitized in uninfected individuals and, consequently, SEA is not effective in inducing changes in expression levels. Supporting this notion, one study has shown that gut TLRs are constitutively non-responsive to the TLR4 ligand LPS (Lotz et al., [@B77]). Factors such as total body parasite burden and infection duration may also play an important role in determining TLR expression levels. Alternatively, differences in polymorphisms within TLR genes or in signaling protein pathways may alter responses to different infectious agent stimuli (Lorenz et al., [@B76]). Finally, lack of SEA effect on uninfected cells may be related to engagement of a second receptor, absent in uninfected cells.

![**Baseline expression of TLRs on B cells (A) and dendritic cells (B).** CD19+ B cells and dendritic cells, were isolated from peripheral blood mononuclear cells using specific isolation kits according manufacturer\'s instructions to a purity of 95--98%. TLR2, TLR4, TLR5, and TLR9 expression was assessed in B cells and monocyte derived dendritic cells from helminth-infected MS patients, uninfected MS patients, and healthy controls, using flow cytometry. Mean fluorescence intensity (MFI) of TLR expression was corrected after subtracting MFI of the control antibody isotype. TLR2 expression in infected MS patients was found to be significantly higher (*p* \< 0.001) than in uninfected MS patients or healthy controls. In contrast, MFI of TLR4, TLR5, and TLR9 did not differ between groups. Data represent mean values ± SEM from 12 subjects for each group.](fcimb-02-00112-g0002){#F2}

![**SEA upregulated TLR2 expression on B cells and dendritic cells, from helminth-infected MS patients.** B cells and dendritic cells were cultured for 48 h in the presence and in the absence of SEA, or PPD used as control antigen. TLR expression was evaluated using flow cytometry, and results expressed as mean fluorescence intensity. Following exposure to SEA, TLR2 was markedly up-regulated in B cells and dendritic cells from helminth-infected MS patients. In contrast, no significant changes were observed in TLR2 expression after PPD exposure. Likewise, exposure to SEA did not affect TLR4, TLR5, or TLR9 expression on B cells or dendritic cells. Data illustrate MFI from a representative patient. Similar results were observed in 11 additional patients.](fcimb-02-00112-g0003){#F3}

TLR are expressed on CNS cells and can also influence local immune responses. There is marked increase in TLR expression both in MS and EAE brain lesions, and cerebro-spinal fluid mononuclear cells (Bsibsi et al., [@B16]). Both murine and human microglia mount specific activation programs suited to different TLR signals, particularly TLR9, linking innate and adaptive immune responses at sites where CD4+ T cells undergo activation or proliferate (Chearwae and Bright, [@B22]; Marta et al., [@B84]). Conversely, it was recently shown that TLR3 triggers neuroprotective responses in astrocytes, controlling the growth of axons and neuronal progenitor cells (Bsibsi et al., [@B15]). Overall, it is clear that TLR are potent modulators of microglia cells and macrophage activation programs in the CNS, as well as of neuroprotective responses. Table [1](#T1){ref-type="table"} summarizes the main biological effects of TLRs on the course of EAE and MS.

###### 

**Biological effects of TLR on EAE and MS**.

  **TLR/ligand**        **Target cell**                              **Biological effects**                                                                                                  **EAE**   **MS**
  --------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- --------- --------
  TLR2/SEA              B cells and DCs                              Upregulation of TLR2; induction of tolerogenic DCs Increased production of eotaxin, IL-5, and IL-13, TGF-β, and IL-10             
                                                                     Suppression of IL-12, IL-6, IL1-β, and TNF-α Down regulation of LPS-induced co-stimulatory molecules on DCs             \+        \+
                                                                     Induction of IL-10 producing Treg cells                                                                                           
  TLR2 and TLR4/HMGB1   Macrophages and microglia                    Increased expression of IL-23                                                                                                     \+
  TLR2/zymosan          DCs                                          Induction of tolerogenic DCs, increased production of IL-10 and TGF-β                                                             
                                                                     Decreased production of IL-6 and IL-12                                                                                  \+        
  TLR3                  Astrocytes                                   Triggers neuroprotective responses, controlling the growth of axons, and neuronal progenitor cells                      \+        \+
  TLR3                  Microglia                                    Th1 cell polarization, increased production of IFN-γ concomitant with increased CD4+ T cell death                       \+        
  TLR4/LPS              T cells                                      Induction of pro-inflammatory Th1 responses                                                                             \+        
                        Myeloid DCs                                  TLR4--/-- mice shown exacerbation of MOG-induced EAE                                                                              
                                                                     Increased production of IL-6 and IL-23 by myeloid DCs                                                                   \+        
                                                                     Increased number of Th17 cells and serum levels of IL-17                                                                          
                                                                     Impaired Th1 responses                                                                                                            
  TLR9/CpG DNA          Myeloid DCs                                  TLR9--/-- mice exhibited ameliorated symptoms of EAE                                                                    \+        
                        Other cells different from DCs and T cells   TLR9--/-- mice exhibited exacerbated symptoms of EAE                                                                    \+        
  TLR9                  Microglia                                    CD4+ T cells undergo activation and proliferation                                                                       \+        \+

DCs, Dendritic cells; HMGB1, High mobility group box chromosomal protein; SEA, Soluble egg antigen.

In addition to TLRs, DCs express a variety of receptors specialized in the recognition of glycans, of which CLRs are the most important (Weis et al., [@B118]). Recent data suggests glycan-induced CLR signaling modulates inflammatory responses by enhancing or suppressing TLR-mediated responses. DC-SIGN especially shows interesting properties associated with Th2 polarization, suppression of inflammation, and induction of regulatory T cell populations (Bergman et al., [@B12]). Mannosylated Mycobacterial cell wall components suppressed LPS-induced TLR4 signaling, indicating crosstalk between DC-SIGN and TLR4 (Geijtenbeek et al., [@B48]). In addition, one particular DC-SIGN has been shown to be specific for the Lewis^x^ determinant present in *S. mansoni*, and may participate in the effects it has shown on the immune response (Kuijk and van Die, [@B71]). Recently, another C-type lectin, DCIR was described as suppressing TLR activation, by inhibiting TLR-8 mediated IL-12 and TNF-α production by DCs (Meyer-Wentrup et al., [@B89]). Physical interaction between CLRs and other receptors at the cell surface may lead to receptor cross-linking and further modification of intracellular signaling (Kuijk and van Die, [@B71]). These observations suggest helminth glycans may target C-type lectins on DCs, further modulating their immunological functions.

Molecular mechanisms involved in TLR binding and signaling pathways
===================================================================

TLR signaling has been extensively investigated in the last several years. The cytoplasmic domain of TLR, termed Toll/interleukin-1 receptor (TIR), is highly conserved and functions as binding site for downstream adaptor molecules. Signaling TLR involves a variety of adaptor proteins (Watters et al., [@B116]), the most common being the myeloid differentiation marker 88 (MyD88) signaling through all TLRs, except TLR3 (O\'Neill and Bowie, [@B95]). Activated TLR recruit MyD88, leading to subsequent activation of downstream targets, including nuclear factor kappa B (NF-κB), mitogen activated protein kinases (MAPKs) (p38, JNK, and ERK1/2), KB kinase inhibitor (IKK), and interferon regulatory factors (IRF; West et al., [@B120]). After endocytosis into endosomes, both TLR3 and TLR4 signal through the TIR-domain-containing adapter, inducing IFN-β (TRIF) to activate downstream signaling. In addition, MyD88 adaptor-like (Mal, also called TIRAP) is recruited by TLR2 and TLR4, and so far, its function appears to be to subsequently stabilize MyD88 in the complex acting as a bridge (O\'Neill, [@B96]; Beutler, [@B14]).

TLR2 has been implicated as a potential receptor for SEA immunomodulatory activities (Table [1](#T1){ref-type="table"}), after observing that schistosome-derived lipids elicited tolerogenic DCs, triggered eotaxin, IL-5, and IL-13 production, and induced IL-10 producing regulatory T cells via TLR2 recognition (van der Kleij et al., [@B110]; Magalhaes et al., [@B78]). Moreover, during experimentally-induced infections, TLR2 absence was associated with enhanced Th1 and reduced Th2 responses, and increasing disease severity (Layland et al., [@B75]). It is generally accepted that schistosoma-derived lipids signal via TLR2, whereas dsRNA from schistosomal eggs activates TLR3 (Aksoy et al., [@B4]).

We have shown that SEA and TLR2 agonists modulate intracellular pathways resulting in suppression of IL-12, IL-6, IL-1β, and TNF-α DC production, and activation of TGF-β, as well as IL-10 production by both DCs and B cells through a MyD88-dependent pathway (Correale and Farez, [@B27]). We also found SEA down-regulated expression of LPS-induced co-stimulatory molecules on DCs in a MyD88-independent manner (Correale and Farez, [@B27]). These patterns of DC response are similar to those observed after stimulation using *Giardia* extracts (Kamda and Singer, [@B65]). Collectively, these observations suggest SEA is able to regulate multiple pathways downstream of TLRs, and that schistosoma contribute to maintain an anti-inflammatory milieu through multiple mechanisms. Supporting these findings, previous studies have demonstrated that mice with B-cell specific deletions of TLR2 and TLR4 or of the TLR adaptor MyD88, do not recover from EAE, indicating TLR participate directly in regulatory functions exerted by B cells (Lampropoulou et al., [@B73]). Likewise, ES-62 a glycoprotein from the rodent nematode *Acanthonema vitae* inhibited both B and T cell activation through the MyD88-dependent TLR4 pathway (Goodridge et al., [@B52]). However, and in contrast to these observations, studies using DCs derived from TLR2^−/−^ and TLR4^−/−^ mice have demonstrated that TLR2 and TLR4 are not required for SEA-pulsed DCs to induce anti-inflammatory responses in naïve mice, suggesting other receptors, such as C-type lectins, may be implicated in DCs response capacity to SEA. Discrepancies between investigations may be due to the presence of different moieties in SEA preparations or, alternatively, differences in parasite Ag recognition between human and mouse TLR2s (Kane et al., [@B67]). Figure [4](#F4){ref-type="fig"} summarizes potential mechanisms for immune regulation mediated by helminths as discussed above.

![**Summary of putative mechanisms through which helminths could modulate MS. (A)** Helminth-derived products influence the development of specific immunosuppressive mechanisms through interactions with dendritic cells, and B cells. **(B)** Signaling-dependent mechanisms generated by helminth products. Binding of carbohydrates or glycolipid helminth-derived products trigger MAPK cascades, resulting in c-Fos phosphorylation. **(C)** Helminth-derived products favor Th2 responses in dendritic cells by signaling-independent pathways mediated by RNAses, cystatins, and cathepsins.](fcimb-02-00112-g0004){#F4}

One of the major signaling cascades triggered as a result of TLRs engagement is the MAPK pathway. Differential activation of MAPK p38 and extracellular-signal-regulated kinase (ERK) in DCs has been associated with varying levels of cell maturation and cytokine production. p38 is thought to be important in DC-maturation, and pro-inflammatory T cell responses, whereas ERK activation has more often been associated with anti-inflammatory and Th2 responses (Agrawal et al., [@B2]; Correale and Farez, [@B27]). Recent analysis of signaling pathways induced in DCs by carbohydrates from *Schistosoma* eggs has indicated that TLR2 agonists induce increased phosphorylation of the MAPK ERK1/2. Neither stimulus showed effect on p38 or JNK1/2 phosphorylation, however. Interestingly, ERK 1/2 activity blockade using the specific inhibitor U0126, significantly enhanced IL-12 and inhibited IL-10 production induced by TLR2 agonists (Agrawal et al., [@B2]; Correale and Farez, [@B27]). In contrast, TLR4 and TLR5 agonists have been shown to preferentially induce IFN-γ and IL-12 via a mechanism involving p38 and JNK1/2 (Rincon et al., [@B103]; Agrawal et al., [@B2]; Marthur et al., [@B85]). ERK 1/2 signaling induced by TLR2 agonists and SEA results in c-Fos phosphorylation (Agrawal et al., [@B2]). Silencing of c-Fos causes marked IL-12 production, behaving like a Th1 stimulus, indicating that the bias toward IL-10 production observed after TLR2 or SEA stimulation is mediated by c-Fos phosphorylation (Agrawal et al., [@B2]). It is unclear at present whether SEA stimulation affects other signaling cascades, such as PI3K/Akt pathway. Identification and characterization of signaling molecules involved in MyD88-indpendent pathways remain a challenge for the future.

Overall, these findings provide evidence that helminth parasites and their antigens modulate TLR expression and consequently the innate immune response, preventing host tissue damage. TLR expression and function can, however, have bystander effects such that responses to non-helminth pathogens are also dampened inducing a protective effect against autoimmune diseases such as MS. These protective effects are mediated mainly by suppression of pro-inflammatory cytokines and activation of IL-10, as well as by expansion of CD4+CD25+ FoxP3+ Treg cells. Furthermore, these mechanisms are dependent on ERK 1/2 signaling resulting in the phosphorylation of the early transcription factor c-Fos.

Parasite antigens may modulate DCs through PPRs-signaling independent mechanisms
================================================================================

Evidence is emerging that helminth manipulation of DCs may also be mediated by mechanisms other than receptor-mediated signaling events, for example, by the enzymatic activities of helminth-derived products (Figure [4](#F4){ref-type="fig"}). Helminth parasites are known to release a wide variety of enzymatically active products that are thought to play an important role in establishing and maintaining infection, by contributing to the degradation of soluble antiparasitic molecules or through impairment of innate immune cells (Everts et al., [@B40]). Omega-1 a glycoprotein derived from schistosoma eggs specifically primes DCs to drive polarized Th2 responses (Everts et al., [@B39]). Although the target receptor is currently unknown it has been suggested that its ribonuclease activity is involved in this effect. Furthermore, a number of studies have documented the potent effects of cystatins, a class of molecules expressed by filiarial nematodes, on host immune responses. Helminth cystatins from *A. vitae, B. Malayi, N. braisliensis*, and *O. volvolus* interfere with DC antigen presentation by blocking host cysteine protease activity (Klotz et al., [@B56]). Bm-CPI-2, a cystatin from *B. Malay* was described as interfering with antigen processing, which led to a reduced number of epitopes presented to T cells *in vitro* (Manoury et al., [@B81]). Recombinant AvCystatin, a cystatin derived from *A. vitae* is recognized by macrophages and upon uptake induces phosphorylation of the mitogen-activated protein kinase signaling pathway ERK1/2 and p38 in macrophages, leading to induce IL-10 secretion (Hartmann et al., [@B59]). Finally, helminth pathogens express cysteine proteases, termed cathepsines, which cause immune deviation by suppressing Th1 immunity. Based on observations of Der p1, one of the major allergens in house dust, it is conceivable for helminth-derived proteases to have the potential to favor Th2 polarization through functional modulation of DC (Hammad et al., [@B58a]). This mechanism is probably mediated by the inhibition of TRIF-dependent signaling via degradation of TLR3 within the endosome (Donelly et al., [@B34]).

Helminth-derived immunomodulatory molecules
===========================================

Whilst the exact signaling pathways by which immune responses are initiated remains obscure, helminth products seem able to interact with host cells and interfere with their function via distinct mechanisms including Treg, B cells and induction of regulatory cytokines such as IL-10 and TGF-β as discussed in the previous sections.

Several studies led to the discovery of specific immunomodulatory helminth-derived molecules and products inducing microenvironments beneficial for parasites while at the same time blocking autoimmune responses (Adisakwattana et al., [@B1]; Danilowicz-Luebert et al., [@B33]). Many helminth molecules are homologous to mammalian cytokines. For example two TGF-β homologs found in *Brugia* species, *Bm-tgh-1* and *Bm-tgh-2* have been well characterized (Gomez-Escobar et al., [@B51]). Similarly, *S. mansoni* male worms express a member of the TGF-β receptor family known as SmRK-1 (Beall and Pearce, [@B11]), and a product secreted by *H. polygyrus* contains remarkable TGF-β-like activity inducing Foxp3 expression in naïve T cells, modulating immune function (Grainger et al., [@B54]).

Another well characterized helminth molecule is ES-62, a glycoprotein from the rodent nematode *A. vitae* which exerts several immunomodulatory effects including inhibition of B- and T-lymphocyte proliferation, inhibition of IFN-γ, IL-12, and IL-17 secretion, and inhibition of maturation of naive DCs priming T cells (Harnett and Harnett, [@B58]). These effects seem to be dependent on phosphorylcholine moieties present on glycoproteins secreted by the parasites. These immunological effects have been observed during therapeutic administration of ES-62 after collagen-induced arthritis induction in mice, resulting in significant reduction of disease severity and progression (Adisakwattana et al., [@B1]; Mastisz et al., [@B86]). Likewise, when rDiAg, a product from the filarial parasite *Dirofilaria immitis*, is administered to NOD mice it completely prevents insulinitis and diabetes onset (Imai et al., [@B63]). Furthermore, *S. mansoni*-specific lysophosphatidylserine activates TLR2 at the cell surface of DCs, generating mature DCs with the ability to promote IL-10 secreting regulatory T cell development. Similarly, other products derived from *S. mansoni* modulate the immune response. Sm16 activates the production of IL-1 receptor antagonists from human keratinocytes, inducing secretion IL-10 and down-regulating ICAM-1 expression. Lacto-N-fucopentose III (LNFP III) contained in Schistosoma eggs is an oligosaccharide that induces IL-10 producing B1 cells in mice (Velupillai et al., [@B113]). SmCKBP secreted from *S. mansoni*, *S. haematobium*, and *S. japonicum* eggs, suppresses inflammation by binding to different chemokine subfamilies (Adisakwattana et al., [@B1]). Finally, products from *Ascaris suum* have also been described to contain immunomodulatory properties. The administration of PAS-1 a 200 kDa protein from *A. suum* to mice that have been injected with LPS results in significant decrease in neutrophil migration, increase in IL-10 production, as well as suppression of IL-6, TNF-α, and IL-1β (Oshiro et al., [@B97]).

Concluding remarks
==================

Parasites inhabit immune-competent hosts for long periods and can therefore develop modulatory molecules, generating strong anti-inflammatory responses that on one hand may restrict host tissue damage, but on the other can also enhance parasite survival. Several studies have demonstrated that chronic helminth infections in particular, but not acute infections, are associated with the expression of regulatory networks necessary for down modulating autoimmune responses to harmless antigens. In addition, worm glycans may play a role in helminth-induced biasing of the immune response, contributing to the observed protection against autoimmune diseases. Significant interest has arisen in defining and characterizing specific helminth molecules with important immunomodulatory capacities as targets for therapeutic applications in the treatment or prophylaxis of autoimmune diseases. It would be dangerous, however, to ignore the fact that this regulatory environment may hamper essential and necessary responses to other antigens, vaccinations, and life-threatening pathogens. The concern exists because wherever helminth infections are prevalent, so too are dangerous microbial agents such as *Mycobacterium tuberculosis*, human immunodeficiency virus, and malarial parasites. Impaired Th1 responses to tetanus toxoid immunization (van Riet et al., [@B112]) and against influenza virus in Schistosoma and Onchocerca infected patients (van Riet et al., [@B111], [@B112]) have also been reported, as well as reduced responses to BCG vaccination and to the cholera vaccine during intestinal helminth infection (Elias et al., [@B36]). Another area of specific safety concern is the possibility of helminths becoming pathogenic in patients with impaired immunity like those treated with immune suppressive medications. For example, S. Stercolaris could multiply and the infection become fulminant when hosts are treated with glucocorticoids (Elliot and Weinstock, [@B37]). Improving current knowledge of these effects is therefore essential for the development of novel therapeutic approaches for the treatment of autoimmune diseases such as MS. It would be critical to focus on the investigation of immunomodulatory helminth-derived molecules to selectively induce regulatory immune responses, and avoid any possible side effects of natural worm infections. Serious efforts should also be made to generate antigen-specific immunoregulation in order to circumvent possible interference with essential responses to other antigens.
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